Kaplan Fox Alerts GoDaddy Inc. (NYSE: GDDY) Investors to an Approaching Lead Plaintiff Deadline on October 20, 2026

A class action lawsuit has been filed against GoDaddy Inc. for allegedly making false and misleading statements about customer growth strategy while implementing promotional discounts that materially harmed bookings growth. The company's stock declined over 14% on February 25, 2026, following disclosure of sharply decelerated bookings growth of only 5% in Q4 2025. The lead plaintiff deadline is October 20, 2026.

10/02/2026, 10:00 AM • GlobeNewswire

Kaplan Fox Notifies Beta Bionics, Inc. (NASDAQ: BBNX) Investors of an Upcoming Lead Plaintiff Deadline on November 3, 2026

A class action lawsuit has been filed against Beta Bionics (NASDAQ: BBNX) for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious device malfunctions in its iLet insulin pump caused by an overly aggressive dosing algorithm. The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about complaint severity, leading to a 37% stock decline. The lead plaintiff deadline is November 3, 2026.

10/02/2026, 10:00 AM • GlobeNewswire

רוזן, משרד מוביל בפריסה ארצית המייצג משקיעים, מעודד את משקיעי חברת Beta Bionics, Inc לשכור ייעוץ משפטי לקראת מועד אחרון חשוב במסגרת תביעה ייצוגית בניירות ערך – BBNX

The Rosen Law Firm is reminding investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 of the November 3, 2026 deadline to file a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false and misleading statements about its iLet Bionic Pancreas insulin pump system, which the FDA found to have serious malfunctions causing dangerous insulin levels and hypoglycemic events. The company allegedly failed to implement corrective measures despite FDA concerns.

10/01/2026, 12:55 AM • GlobeNewswire

Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX

Beta Bionics faces a securities class action lawsuit alleging the company failed to disclose that its iLet insulin pump had a malfunctioning automated dosing algorithm causing dangerously high insulin delivery and hypoglycemic events. The company allegedly received thousands of complaints it failed to report to the FDA, and an FDA Form 483 identified over 18,000 unreported complaints. Investors with losses exceeding $100,000 have until November 3, 2026 to file lead plaintiff applications.

09/30/2026, 11:45 PM • GlobeNewswire

ROSEN, TOP-RANKED TRIAL ATTORNEYS, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS

Rosen Law Firm has filed securities class action lawsuits against Doximity, Inc., Qfin Holdings, Inc., and Beta Bionics, Inc., alleging investor damages. The primary case detailed involves Doximity, which allegedly overstated its Newsfeed's revenue impact and lost market share to competitors. Investors have until November 16, 2026 to serve as lead plaintiff.

09/30/2026, 9:34 PM • GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Qfin Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QFIN

Rosen Law Firm has filed class action lawsuits against Qfin Holdings, Inc. for allegedly making false and misleading statements about business resilience and downplaying regulatory impacts during the Class Period (March 18, 2026 - August 25, 2026). Investors who purchased securities during this period may be eligible for compensation. The deadline to serve as lead plaintiff is November 30, 2026.

09/30/2026, 7:28 PM • GlobeNewswire

ROSEN, A NATIONAL AND LEADING INVESTOR RIGHTS FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Rosen Law Firm is soliciting investors in Beta Bionics, Inc. (NASDAQ: BBNX) who purchased stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, concealing that the FDA had raised serious safety concerns including device malfunctions causing dangerously high insulin dosing and thousands of complaints. The lead plaintiff deadline is November 3, 2026.

09/30/2026, 7:15 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose serious safety deficiencies, quality management issues, and unreported customer complaints involving serious injuries. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.

09/30/2026, 12:00 PM • GlobeNewswire

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC announces class action securities lawsuits against Beta Bionics, Inc. and York Space Systems, Inc. Beta Bionics faces allegations of failing to disclose that its iLet insulin pump malfunctioned, delivering dangerously high insulin levels and causing life-threatening hypoglycemic events. The company allegedly received thousands of complaints it failed to report to the FDA. York Space Systems and Simply Good Foods Company also face similar securities fraud allegations. Investors have until specified deadlines to request lead plaintiff status.

09/29/2026, 10:01 PM • GlobeNewswire

DEADLINE ALERT for DKS and BBNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Class action lawsuits have been filed against DICK's Sporting Goods (DKS) and Beta Bionics (BBNX) for allegedly making materially false and misleading statements to investors. DKS is accused of failing to disclose issues with Foot Locker inventory and exposure to industry-wide promotional pressures. BBNX is accused of omitting FDA Form 483 safety issues and failing to disclose life-threatening complaints. Lead plaintiff deadlines are set for November 3, 2026.

09/25/2026, 12:08 PM • GlobeNewswire

BBNX Stock Drop Alert: Beta Bionics Stock Plummets 37% after Medical Device Safety Issues Revealed – BFA Law Notifies Investors of the Imminent November 3 Deadline

Beta Bionics (NASDAQ: BBNX) faces a securities fraud class action lawsuit after its stock dropped 37% in January 2026. The company allegedly misled investors about the safety and efficacy of its iLet insulin pump, which experienced over 18,000 unreported complaints involving life-threatening hypoglycemia. The FDA issued a warning letter citing the company's failure to report device malfunctions. Investors have until November 3, 2026 to join the lawsuit.

09/25/2026, 6:37 AM • GlobeNewswire

BBNX Stockholders Have Rights – If You Lost Money Investing in Beta Bionics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company downplayed FDA Form 483 concerns in October 2025, claiming issues were minor, but the FDA's February 2026 warning letter revealed serious malfunctions causing dangerous insulin overdoses. BBNX stock plummeted from $31.99 to $12.89 per share between January and February 2026. Investors who suffered losses during the class period (July 30, 2025 - February 24, 2026) may be eligible to recover damages.

09/24/2026, 7:16 PM • GlobeNewswire

BBNX Investors: Beta Bionics, Inc. Shares Declined By $11.85 On January 9, 2026 -- Contact Kirby McInerney LLP to Discuss Your Rights

Kirby McInerney LLP has filed securities fraud class action lawsuits against three companies. Beta Bionics faces allegations of concealing malfunctioning insulin pumps causing dangerous hypoglycemic events and FDA regulatory issues, resulting in a 37% stock decline on January 9, 2026. Lincoln Educational Services and FuelCell Energy also experienced significant stock price declines on August 10 and September 2, 2026, respectively, prompting similar legal action.

09/24/2026, 6:00 PM • GlobeNewswire

LINC Investors: Lincoln Educational Services Shares Declined By $10.22 On August 10, 2026 -- Contact Kirby McInerney LLP to Discuss Your Rights

Kirby McInerney LLP has filed securities fraud class action lawsuits against three companies for alleged false and misleading statements. Lincoln Educational Services shares fell 24.93% after revealing student starts grew only 1% despite 9% enrollment growth. Beta Bionics and FuelCell Energy also experienced significant share price declines. Investors who suffered losses are urged to contact the firm by November 10, 2026 to potentially serve as lead plaintiffs.

09/24/2026, 6:00 PM • GlobeNewswire

ALARUM DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Alarum Technologies Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALAR

Rosen Law Firm is reminding investors in Alarum Technologies Ltd. (ALAR), Beta Bionics, Inc. (BBNX), and XTI Aerospace, Inc. (XTIA) of upcoming lead plaintiff deadlines in securities class action lawsuits. The primary case involves Alarum Technologies, where defendants allegedly made false statements about a subsidiary's illegal activity linking customer internet devices to networks without consent, which heightened legal exposure and threatened business prospects.

09/24/2026, 5:42 PM • GlobeNewswire